iPSC-derived extracellular vesicles rescue deficits in human and mouse models of Parkinson’s disease
iPSC-derived extracellular vesicles rescue deficits in human and mouse models of Parkinson’s disease
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Publication status: preprint
A plain-language reading has not been prepared for this paper yet.
Original abstract
Parkinson’s disease (PD) pathogenesis often involves progressive α-synuclein (α-Syn)-mediated neuronal dysfunction, yet the earliest cellular events that link α-Syn pathology to circuit failure remain poorly defined. Here, we used human induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neurons from patients carrying the familial A53T SNCA mutation to reconstruct a temporal course of dysfunction in vitro . We identified a biphasic trajectory with an early phase of hyperexcitability, characterized by elevated spontaneous firing, followed by a progressive transition into hypoexcitability as the neurons mature, accompanied by reduced network activity, synaptic dysfunction, and α-Syn accumulation. Transcriptomic profiling at the critical transition point revealed a dual transcriptional signature, with upregulation of stress-inflammatory pathways (p53, JAK-STAT, apoptosis) coupled with systematic downregulation of metabolic and synaptic maintenance genes. This molecular profile preceded functional collapse, linking early hyperactivity-driven metabolic stress to subsequent neuronal exhaustion. To counteract this pathology, we used extracellular vesicles (EVs), small membrane-bound particles carrying intercellular signals, as a cell-free treatment approach. Strikingly, treatment with EVs derived from healthy iPSCs completely rescued both electrophysiological deficits and pathological α-Syn accumulation, restoring normal firing patterns, synaptic function, and network activity. Consistent with these observations, EV treatment reduced α-Syn aggregation and improved motor responses in α-Syn fibril-injected mice, which are characterized by pathological α-Syn accumulation and motor deficits. Overall, these findings demonstrate that EVs derived from healthy iPSCs can reverse PD-related phenotypes in human and mouse models.